ReviewThe international journal of neuropsychopharmacology2025

From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials.

Jonathan M Meyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.